医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Prestige Biopharma Receives 2022 Asia-Pacific Bioprocessing Excellence Awards

2022年04月01日 AM09:00
このエントリーをはてなブックマークに追加


 

SINGAPORE

Prestige Biopharma Limited a Singapore-based leading biopharmaceutical with operations in USA and South Korea, announced that the company has been recognized as the grand winner of the Bioprocessing Excellence in SEA (South-East Asia).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005633/en/

(Photo: Business Wire)

(Photo: Business Wire)

The Awards Ceremony was held in conjunction with the 9th Biologics Manufacturing Asia and 6th Biologistics World Asia 2022 hybrid Conference, which was streamed live on 29 – 30 March 2022.

Asia Pacific Bioprocessing Excellence Awards recognizes exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality. The panel of expert judges include key opinion leaders with more than 20 years of experience from all the key players in Asia and globally.

“We are very proud to receive this award and thank you for recognizing Prestige’s passion for driving innovation and change in bioprocessing,” said Dr. Deborah Moshinsky, Head of Global R&D of Prestige in her acceptance speech. “Prestige Group has undergone a significant expansion to our manufacturing capabilities. Our EU-GMP certified facility with global compliance recognition is currently expanding its capacity up to 234,000 liters through its 2nd Campus developments.”

Prestige has developed biosimilars and first-in-class antibody drugs of high quality and strong cost competitiveness in expedited development programmes, with its proprietary bioprocessing technology.

Prestige’s leading pipeline HD201 trastuzumab (Tuzune®) is currently under EU EMA’s MAA review and its manufacturing facility, Prestige Biologics, has received European Union Good Manufacturing Practices (GMP) certification last February.

The company’s robust pipeline in clinical stage also includes an innovative therapy for pancreatic cancer, PBP1510 (INN: Ulenistamab) in Phase 1/2a clinical trial in Europe, an Avastin biosimilar HD204 (Vasforda®) in global Phase 3, and a Humira biosimilar PBP1502 in Phase 1 clinical trial in Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005633/en/

CONTACT

Media enquiries:

Global Communication Team

Prestige Biopharma Ltd.

www.prestigebiopharma.com

Yujin Suh

Tel: +65-6924-6535

info@prestigebio.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June
  • IntelliCentrics Seeks Strategic Alliance With Taiwanese Health Insurance Providers to Serve Millions of Taiwanese Patients Ensuring They Have Remote Access to Trusted, High Quality Healthcare.
  • 中智全球寻求与台湾医疗保险公司结成战略联盟,为数百万台湾患者提供服务,确保他们能够远程获得可靠及优质的医疗保健服务。
  • Sermo调查显示,今年ASCO的与会肿瘤学家对新的肺癌和乳腺癌研究最感兴趣
  • 訂正・差し替え SCAI 2022 Scientific Meeting で心原性ショックの予後改善に向けた Impella の研究と進歩を大きく紹介